ArticleNeurocritical care2011
The use of lacosamide in refractory status epilepticus.
Article in Neurocritical care, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Guidelines for the evaluation and management of status epilepticus.Neurocritical care · 2012Guideline
- In-hospital outcomes of lacosamide versus levetiracetam for early adjunctive treatment of status epilepticus: A Nationwide Japanese retrospective cohort study.Epilepsia open · 2026Observational
- Review and Updates on the Treatment of Refractory and Super Refractory Status Epilepticus.Journal of clinical medicine · 2021Review
- Super-Refractory Status Epilepticus: Prognosis and Recent Advances in Management.Aging and disease · 2021Review
- Treatment of Refractory Convulsive Status Epilepticus: A Comprehensive Review by the American Epilepsy Society Treatments Committee.Epilepsy currents · 2020Article
- Safety and Efficiency of Intravenous Push Lacosamide Administration.Neurocritical care · 2018Article
- Review
- Article
- The efficacy of lacosamide as monotherapy and adjunctive therapy in focal epilepsy and its use in status epilepticus: clinical trial evidence and experience.Therapeutic advances in neurological disorders · 2017Review
- Observational study of intravenous lacosamide in patients with convulsive versus non-convulsive status epilepticus.Clinical drug investigation · 2015Observational
- Intravenous lacosamide in refractory seizure clusters and status epilepticus: comparison of 200 and 400 mg loading doses.Neurocritical care · 2014Observational
- Refractory status epilepticus.Annals of Indian Academy of Neurology · 2014Article
- Usefulness of intravenous lacosamide in status epilepticus.Journal of neurology · 2013Article
- Practice variations in the management of status epilepticus.Neurocritical care · 2012Article
- Use of lacosamide in children with refractory epilepsy.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2012Article
- Safety and efficacy of lacosamide in the intensive care unit.Neurocritical care · 2012Article
- Novel medications for epilepsy.Drugs · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCase reports suggest lacosamide may have a role in status epilepticus (SE). The purpose of this case series is to describe the use of lacosamide in refractory SE (RSE) at our institution.
methodsObservational study of all patients admitted to the neurosciences intensive care unit with RSE who received at least one dose of lacosamide from October 2009 to September 2010.
resultsNine patients received lacosamide after failure of at least two other agents. Lacosamide was started a median of 2 days (range: 0-14 days) after the onset of SE. The most frequently used dosing regimen was an initial intravenous dose of 200 mg followed by 200 mg every 12 h. Most patients had received 3 (range: 2-5) AEDs prior to lacosamide. Levetiracetam was used prior to lacosamide in all cases. No patients evaluated responded to lacosamide according to our predefined criteria. One patient developed angioedema after receiving two doses; another patient developed angioedema where timing in relation to the lacosamide was unclear. Care was withdrawn in three of the nine patients for reasons unrelated to lacosamide. Lacosamide was continued at discharge on all surviving patients except in one case of angioedema.
conclusionsThis is the largest case series to date describing the use of lacosamide in patients with RSE. Despite the novel mechanism of action, we observed no evidence that lacosamide is effective in RSE; however, our sample size was small. Further study is needed to determine the role of lacosamide in SE, especially early in the treatment course.
Indexed as
Identifiers
21249530What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.